Changes in net revenues as compared to the second quarter of the prior year were primarily driven by:
Glucagon sales increased primarily due to an increase in unit volumes, as a result of two suppliers discontinuing their glucagon injection products at the end of 2022
Phytonadione sales increased due to increased unit volumes, as a result of supplier shortages
Primatene MIST® sales decreased due to a decrease in unit volumes, as a result of inventory drawdowns by retailers
The decrease in sales of epinephrine and lidocaine was primarily due to a decrease in unit volumes, as a result of suppliers returning to their historical distribution levels
The decrease in sales of enoxaparin and naloxone was primarily due to a decrease in unit volumes
Other finished pharmaceutical product sales increased primarily due to:
An increase in unit volumes for dextrose, atropine, calcium chloride, and sodium bicarbonate, due to increasing demand caused by supplier shortages
A full quarter of sales for ganirelix and vasopressin, which were launched in June 2022 and August 2022, respectively
Launch of regadenoson in April 2023
Active Pharmaceutical ingredient ("API") sales increased primarily due to the timing of customer purchases
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.